Gilead Sciences (LTS:0QYQ) Cyclically Adjusted FCF per Share: $8.87 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0QYQ Gilead Sciences Inc LTS:0QYQ
80 GF Score
Price $133.00
GF Value $104.82
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Gilead Sciences Cyclically Adjusted FCF per Share?

Gilead Sciences LTS:0QYQ +2.31% 80 Cyclically Adjusted FCF per Share is $8.87 as of Jun. 2026. GuruFocus rates LTS:0QYQ with a GF Score™ of 80/100 and a GF Value™ of $104.82 (Modestly Overvalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Gilead Sciences's adjusted free cash flow per share for the three months ended in Jun. 2026 was $2.762. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $8.87 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Gilead Sciences's average Cyclically Adjusted FCF Growth Rate was -100.00% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -0.20% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 5.60% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 10.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Gilead Sciences was 97.90% per year. The lowest was -0.20% per year. And the median was 25.00% per year.

As of today (2026-08-09), Gilead Sciences's current stock price is $133.00. Gilead Sciences's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was $8.87. Gilead Sciences's Cyclically Adjusted Price-to-FCF of today is 14.99.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Gilead Sciences was 20.44. The lowest was 6.45. And the median was 10.34.


Gilead Sciences  (LTS:0QYQ) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Gilead Sciences's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=133.00/8.87
=14.99

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Gilead Sciences was 20.44. The lowest was 6.45. And the median was 10.34.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Gilead Sciences Cyclically Adjusted FCF per Share Related Terms


Gilead Sciences Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Gilead Sciences's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gilead Sciences Cyclically Adjusted FCF per Share Chart

Gilead Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.19 8.97 9.77 9.82 9.06

Gilead Sciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.29 9.38 9.06 8.91 8.87

LTS:0QYQ vs PFE, BMY, AMGN: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - General subindustry, Gilead Sciences's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gilead Sciences Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's Cyclically Adjusted Price-to-FCF falls into.


LTS:0QYQ
80GF Score
Gilead Sciences Inc LTS:0QYQ
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gilead Sciences Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Gilead Sciences's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=2.762/333.9520*333.9520
=2.762

Current CPI (Jun. 2026) = 333.9520.

Gilead Sciences Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 3.133 241.428 4.334
201612 2.543 241.432 3.518
201703 2.127 243.801 2.914
201706 2.584 244.955 3.523
201709 1.945 246.819 2.632
201712 1.920 246.524 2.601
201803 1.559 249.554 2.086
201806 0.976 251.989 1.293
201809 1.565 252.439 2.070
201812 1.622 251.233 2.156
201903 1.044 254.202 1.372
201906 1.689 256.143 2.202
201909 1.930 256.759 2.510
201912 1.866 256.974 2.425
202003 0.996 258.115 1.289
202006 1.931 257.797 2.501
202009 1.661 260.280 2.131
202012 1.354 260.474 1.736
202103 1.937 264.877 2.442
202106 1.744 271.696 2.144
202109 2.468 274.310 3.005
202112 2.416 278.802 2.894
202203 1.262 287.504 1.466
202206 1.317 296.311 1.484
202209 2.146 296.808 2.415
202212 1.886 296.797 2.122
202303 1.297 301.836 1.435
202306 1.748 305.109 1.913
202309 1.299 307.789 1.409
202312 1.557 306.746 1.695
202403 1.695 312.332 1.812
202406 0.955 314.175 1.015
202409 3.324 315.301 3.521
202412 2.211 315.605 2.340
202503 1.313 319.799 1.371
202506 0.574 322.561 0.594
202509 3.159 324.800 3.248
202512 2.494 324.054 2.570
202603 1.935 330.213 1.957
202606 2.762 333.952 2.762

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $8.87 mean?
Gilead Sciences (LTS:0QYQ) has a Cyclically Adjusted FCF per Share of $8.87 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Gilead Sciences and its competitors.
Is Gilead Sciences' Cyclically Adjusted FCF per Share too high?
Gilead Sciences' current Cyclically Adjusted FCF per Share is $8.87. Overall, Gilead Sciences has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gilead Sciences' Cyclically Adjusted FCF per Share compare to PFE and BMY?
Gilead Sciences' Cyclically Adjusted FCF per Share of $8.87 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Gilead Sciences and its competitors. Gilead Sciences's current Cyclically Adjusted FCF per Share is $8.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gilead Sciences stock overvalued right now?
Based on GuruFocus' analysis, Gilead Sciences (LTS:0QYQ) is currently considered Modestly Overvalued. The stock's GF Value™ is $104.82, compared to a current price of $133.00 — trading 26.9% above its estimated fair value. The current Cyclically Adjusted FCF per Share is $8.87. Gilead Sciences' overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Gilead Sciences (LTS:0QYQ), the current Cyclically Adjusted FCF per Share is $8.87 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gilead Sciences (LTS:0QYQ) Overvalued in 2026?

Based on GuruFocus' analysis, Gilead Sciences stock appears to be overvalued. The current stock price of $133.00 is trading 26.9% above its estimated GF Value™ of $104.82. GuruFocus considers Gilead Sciences to be Modestly Overvalued.

Key valuation signals for LTS:0QYQ:

  • Cyclically Adjusted FCF per Share: $8.87
  • GF Value™: $104.82 vs. price of $133.00 (26.9% above fair value)
  • GF Score™: 80/100 with 3 warning signs

No single metric tells the full story. See the LTS:0QYQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Gilead Sciences Business Description

Address 333 Lakeside Drive, Foster City, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
80GF Score

Get the complete analysis for LTS:0QYQ

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$133.00
Price
$104.82
GF Value